• 30396 Citations
  • 87 Scopus h-Index
19962019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1996 2019

Filter
Review article
2019
Fluorodeoxyglucose F18
Multiple Myeloma
tomography
Bone Marrow
Tomography
3 Citations (Scopus)

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M. V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Serra, E. R., Du, J., van de Donk, N., Berdeja, J. G., Terpos, E., Zamagni, E., Kyle, R. A., San Miguel, J., Goldschmidt, H., Giralt, S., Kumar, S. K. & 15 others, Raje, N., Ludwig, H., Ocio, E., Schots, R., Einsele, H., Schjesvold, F., Chen, W. M., Abildgaard, N., Lipe, B. C., Dytfeld, D., Wirk, B. M., Drake, M. M., Cavo, M., Lahuerta, J. J. & Lentzsch, S., Jun 1 2019, In : The Lancet Oncology. 20, 6, p. e302-e312

Research output: Contribution to journalReview article

Plasma Cells
Multiple Myeloma
Therapeutics
Bone Marrow
Bone and Bones
7 Citations (Scopus)

Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing

Kumar, S. K., Buadi, F. K. & Rajkumar, S. V., Feb 14 2019, In : Blood. 133, 7, p. 652-659 8 p.

Research output: Contribution to journalReview article

Autografts
Stem Cell Transplantation
Stem cells
Multiple Myeloma
Therapeutics
1 Citation (Scopus)

Targeted management strategies in multiple myeloma

Kumar, S. K., Jan 1 2019, In : Cancer Journal (United States). 25, 1, p. 59-64 6 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Clonal Evolution
Therapeutics
Drug Combinations
Treatment Failure
8 Citations (Scopus)

Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline

Mikhael, J. R., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S. K., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., Omel, J., Peswani, N., Prica, A., Raje, N., Seth, R., Vesole, D. H., Walker, I., Whitley, A., Wildes, T. M., Wong, S. W. & 1 others, Martin, T., Jan 1 2019, In : Journal of Clinical Oncology. 37, 14, p. 1228-1263 36 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Practice Guidelines
Joints
Guidelines
Radiation Oncology
2018
5 Citations (Scopus)

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

Richardson, P. G., San Miguel, J. F., Moreau, P., Hajek, R., Dimopoulos, M. A., Laubach, J. P., Palumbo, A., Luptakova, K., Romanus, D., Skacel, T., Kumar, S. K. & Anderson, K. C., Nov 1 2018, In : Blood Cancer Journal. 8, 11, 109.

Research output: Contribution to journalReview article

Multiple Myeloma
Clinical Trials
Therapeutics
Controlled Clinical Trials
Costs and Cost Analysis
48 Citations (Scopus)

Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond

Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M., Giralt, S., Mateos, M. V., Leleu, X. & Anderson, K. C., Feb 1 2018, In : Leukemia. 32, 2, p. 252-262 11 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Immunotherapy
Antibodies
Dexamethasone
Disease-Free Survival
35 Citations (Scopus)

Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C. A., Kang, Y., Kassim, A., Liedtke, M., Malek, E., Martin, T. & 10 others, Neppalli, V. T., Omel, J., Raje, N., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Weber, D., Yahalom, J., Kumar, R. & Shead, D. A., Jan 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 1, p. 11-20 10 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Guidelines
Aftercare
Therapeutics
2017
9 Citations (Scopus)

New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib

Richardson, P. G., Kumar, S. K., Laubach, J. P., Paba-Prada, C., Gupta, N., Berg, D., van de Velde, H. & Moreau, P., Aug 22 2017, In : Journal of Blood Medicine. 8, p. 107-121 15 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Quality of Life
Proteasome Inhibitors
Therapeutics
Patient Safety
98 Citations (Scopus)

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengass, J., Engelhardt, M., Usmani, S. Z., Vesole, D. H., San-Miguel, J., Kumar, S. K., Richardson, P. G., Mikhael, J. R., da Costa, F. L., Dimopoulos, M. A., Zingaretti, C., Abildgaard, N., Goldschmidt, H., Orlowski, R. Z. & 8 others, Chng, W. J., Einsele, H., Lonial, S., Barlogie, B., Anderson, K. C., Rajkumar, S. V., Durie, B. G. M. & Zamagni, E., Apr 1 2017, In : The Lancet Oncology. 18, 4, p. e206-e217

Research output: Contribution to journalReview article

Fluorodeoxyglucose F18
Plasma Cells
Multiple Myeloma
Plasmacytoma
Residual Neoplasm
41 Citations (Scopus)

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

Dingli, D. M., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A., Fonseca, R., Gertz, M., Gonsalves, W., Hayman, S. R., Kapoor, P., Kourelis, T., Kumar, S. K., Kyle, R. A., Lacy, M., Leung, N., Lin, Y., Lust, J. A., Mikhael, J. R., Reeder, C. B., Roy, V. & 7 others, Russell, S. J., Sher, T., Stewart, A. K., Warsame, R., Zeldenrust, S. R., Rajkumar, S. V. & Chanan Khan, A. A., Apr 1 2017, In : Mayo Clinic Proceedings. 92, 4, p. 578-598 21 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Guidelines
Recurrence
Patient Care
Therapeutics
2016
22 Citations (Scopus)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

Tandon, N., Ramakrishna, V. & Kumar, S. K., May 6 2016, In : Clinical Pharmacology: Advances and Applications. 8, p. 35-44 10 p.

Research output: Contribution to journalReview article

Histone Deacetylase Inhibitors
Multiple Myeloma
Therapeutics
Proteasome Inhibitors
Fatal Outcome
431 Citations (Scopus)

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Kumar, S. K., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M. V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W. J., Usmani, S. Z., Zamagni, E. & 20 others, Shimizu, K., Jagannath, S., Johnsen, H. E., Terpos, E., Reiman, A., Kyle, R. A., Sonneveld, P., Richardson, P. G., McCarthy, P., Ludwig, H., Chen, W., Cavo, M., Harousseau, J. L., Lentzsch, S., Hillengass, J., Palumbo, A., Orfao, A., Rajkumar, S. V., Miguel, J. S. & Avet-Loiseau, H., Aug 1 2016, In : The Lancet Oncology. 17, 8, p. e328-e346

Research output: Contribution to journalReview article

Residual Neoplasm
Multiple Myeloma
Bone Marrow Diseases
Clinical Trials
Bone Marrow Cells
41 Citations (Scopus)

New investigational drugs with single-agent activity in multiple myeloma

Rajan, A. M. & Kumar, S. K., Jul 29 2016, In : Blood Cancer Journal. 6, 7, p. e451

Research output: Contribution to journalReview article

Investigational Drugs
Multiple Myeloma
Proteasome Inhibitors
Kinesin
Cyclin-Dependent Kinases